

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.



Europäische Patentamt
Europ. an Patent Offic
Office européen des brevets



(11) Publication number : 0 314 689 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication of patent specification :
01.04.92 Bulletin 92/14

(51) Int. Cl.⁵ : A61K 47/00, A61K 9/22,
A61K 9/52

(21) Application number : 87904411.3

(22) Date of filing : 12.06.87

(86) International application number :
PCT/SE87/00279

(87) International publication number :
WO 88/00059 14.01.88 Gazette 88/02

(54) A CONTROLLED-RELEASE COMPOSITION FOR A BIOLOGICALLY ACTIVE MATERIAL DISSOLVED OR DISPERSED IN AN L2-PHASE.

(30) Priority : 01.07.86 SE 8602931

(73) Proprietor : DRILLETEN AB
Jägershillgatan 15
S-213 75 Malmö (SE)

(43) Date of publication of application :
10.05.89 Bulletin 89/19

(72) Inventor : ENGSTRÖM, Sven
Stävgränd 11
S-902 63 Umeå (SE)
Inventor : LARSSON, Kare, Viktor
Norra Villavägen 7B
S-237 00 Bjärred (SE)
Inventor : LINDMAN, Björn
Helgonavägen 19
S-223 63 Lund (SE)

(45) Publication of the grant of the patent :
01.04.92 Bulletin 92/14

(74) Representative : Henningsson, Gunnar et al
Awapatent AB Box 45086
S-104 30 Stockholm (SE)

(84) Designated Contracting States :
AT BE CH DE FR GB IT LI LU NL SE

(56) References cited :
DE-A- 3 224 619
DK-B- 143 438

EP 0 314 689 B1

Note : Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

Description

The present invention relates to the field of encapsulating biologically active materials in order to obtain a sustained release thereof as is desirable within many different technical fields, such as for instance to have a longer lasting effect of a pharmaceutically active material. More specifically the invention relates to a novel encapsulating material or system which is thermodynamically stable, which is useful for water-soluble as well as water-insoluble biologically active compounds and which enables a highly reproducible sustained release of said biologically active compounds. With reference to last-mentioned property the term "controlled release" will be used throughout description and claims to emphasize the fact that by the present invention the desired sustained release of any active compound can be obtained in a controlled way.

One technique of encapsulating biologically active materials for sustained-release purposes is disclosed in US Patent Specifications Nos. 4,016,100; 4,145,410; 4,235,871; and 4,241,046. In these applications polymer-water preparations or systems are utilized as encapsulating materials. These preparations are, however, thermodynamically unstable (dispersions, emulsions and vesicles) and consist of at least two phases.

The present invention is based on the use of a fundamentally different system, viz. a thermodynamically stable one-phase composition having a well-defined structure, by which it has turned out possible to eliminate or at least drastically reduce disadvantages associated with the above-mentioned prior art compositions.

The new composition or system used according to the present invention is a non-toxic liquid phase formed from certain amphiphilic substances and a polar liquid and is called an L2-phase. The L2-phase is a phase known per se but as far as we know of it has previously not been used for the purposes of the present invention. However, for a better understanding of the invention the present information can be given concerning amphiphilic substances and the L2-phase.

Amphiphilic substances are substances with hydrophilic as well as hydrophobic (lipophilic) groups and such substances spontaneously tend to self-associate in aqueous systems forming various types of aggregates. The L2-phase is one such phase. The L2-phase is a liquid phase with water-aggregates in a hydrocarbon-continuous medium (see Ekwall, P., *Advances in Liquid Crystals*, Ed. G.W. Brown, Academic Press, New York, 1975). The phase can exist in equilibrium with water or a dilute aqueous solution. It is known that oils, like soybean oil, and water can form such a phase in the presence of monoglycerides of unsaturated fatty acids, such as

sunflower oil monoglycerides (see Fennell et al. *J. Colloid Interface Sci.* 93 (1983) 453). Further information about L2-phases will be given below in connection with the disclosure of the invention.

By the present invention there is accomplished a controlled release composition for a biologically active material which composition shows several advantages as compared to the prior art compositions. As was mentioned above this is obtained by using a special L2-phase as the encapsulating material. More specifically the composition according to the present invention is characterized in that the biologically active material is dissolved or dispersed in an L2-phase comprising (a) at least one monoglyceride of an unsaturated fatty acid having 16-22 carbon atoms or a vegetable or animal oil containing such a monoglyceride, (b) at least one triglyceride of at least one unsaturated fatty acid having 16-22 carbon atoms or a vegetable or animal oil containing such triglycerides and (c) at least one polar liquid selected from water, glycerol, ethylene glycol and propylene glycol.

The above-mentioned L2-phase is advantageous for the purposes according to the invention inter alia for the following reasons:

It is thermodynamically stable and therefore, it has no tendency to phase separate with time (unless chemical decomposition occurs).

It has distinct hydrophilic and hydrophobic domains, which enables it to dissolve (solubilize) or disperse both water-soluble and water-insoluble compounds.

The distinct hydrophilic and hydrophobic domains represent an organized structure that puts restrictions on the diffusion of added compounds, a fact which can be advantageously used for controlled-release purposes. Thus, the release rate of a bioactive substance is determined by the outer surface of the phase towards the surrounding medium and the proportions between hydrophilic and hydrophobic domains within the phase. As was mentioned above the L2-phase used in accordance with the present invention comprises or consists of a special liquid monoglyceride, a special liquid triglyceride and a polar liquid. Once these three components of the system have been specified in each single case, the exact composition of the corresponding L2-phase can be found in the prior art, e.g. from a ternary phase diagram. An example of such a phase diagram is shown in Fig. 1 of the drawing which shows the phase diagram for the system of sunflower oil monoglyceride/soybean oil/water at 40°C and 90°C. The two-phase regions and three-phase triangles are marked only at 40°C. Notations: L2, isotropic "oily" solution; C, cubic liquid crystalline phase; D, lamellar liquid crystalline phase; F, reversed hexagonal liquid-crystalline phase. Concentrations in % (w/w). At room temperature the L2-phase has a maximum content of

water of about 12-14% (w/w), and substances localized in the aqueous regions or aggregates will have a highly reproducible sustained release into an outside water phase (or polar liquid phase, respectively).

Generally, the monoglyceride is a monoglyceride of an unsaturated fatty acid having 16-22 carbon atoms. However, often it is not necessary or rather preferable not to utilize said monoglyceride in the pure form but to use instead a natural product containing the same, such as a vegetable or animal oil containing the desired monoglyceride.

According to a preferable embodiment of the composition of the invention the monoglyceride is a monoglyceride of an unsaturated fatty acid having 18 carbon atoms or a vegetable or animal oil containing the same. An especially preferable monoglyceride from this group is monoolein or monolinolein or a vegetable or animal oil containing the same.

The triglyceride used is a triglyceride of at least one unsaturated fatty acid having 16-22 carbon atoms but also in this case a natural product containing said triglyceride can replace the same, such as a vegetable or animal oil containing the desired triglyceride.

A preferred composition according to the invention contains as said triglyceride a triglyceride of at least one unsaturated fatty acid having 18 carbon atoms or a vegetable or animal oil containing the same, an especially preferable oil being soybean oil.

The polar liquid utilized in the claimed composition is preferably water, but said water can also be partly or fully replaced by glycerol, ethylene glycol and/or propylene glycol, which polar liquids can be used for fine adjustments of the release rates of biologically active materials from the L2-phase. That is different polar liquids or different proportions between polar liquids can be used to control the release rate of a specific active material. For such a control or adjustment of the release rate common salt, i.e. sodium chloride, can also be used.

As was mentioned above the exact composition of a specific L2-phase is taken from a phase diagram while taking into consideration the desired release rate for the active compound to be encapsulated, which rate is determined by a person skilled in the art by simple routine experiments. However, a preferable weight ratio of monoglyceride to triglyceride is within the range of from 1:1 to 3:1, more preferably from 2:1 to 2,5:1 and especially 7:3. The content of water (or other polar liquid) is generally determined by the maximum water content of the L2-phase region, which is often not above 12-14% (w/w). Therefore, a suitable water content is within the range of 4-12, preferably 5-10 %.

With reference to the term "biologically active material" or similar as used throughout the specification and claims it means a compound or composition which when present in an effective amount, reacts

with and/or affects living cells and organisms.

One interesting group of compounds to be encapsulated in accordance with the present invention is the group of pharmaceutical compounds, e.g. antibiotics, proteins, steroids, vitamins and nucleic acids, penicillin being an example of antibiotic, insulin an example of a protein and oestriol and prostaglandins examples of steroids.

In connection with proteins it can also be mentioned that an L2-phase exists in connection with fat digestion and absorption in the intestine (see Lindström et al., Lipids 19, 1981, 749). We have found that this L2-phase can protect sensitive substances, like peptides, from degradation in the gastric environment until they are absorbed. Furthermore, an increased uptake has been observed. This L2-phase can function as a vehicle providing chemical protection and controlled uptake in oral administration of drugs and, thus, in certain cases even an improved uptake in the intestinal system.

The composition according to the invention when used as a pharmaceutical composition is prepared with a carrier suitable for oral, rectal or transdermal administration or suitable for inhalation.

Another example of a biologically active material to be encapsulated in accordance with the principles of the present invention is a compound for agricultural use, such as pesticides, fertilizers and trace elements.

Still another example of an interesting active compound in this connection is a feromone but any active substance that can be dissolved or dispersed in the L2-phase should be encapsulable in accordance with the invention.

Generally, the biologically active material is present in an amount of 0,1-10% by weight of a ready-to-use composition, although the invention is not limited to said amounts.

According to another aspect of the invention a method of preparing the above-mentioned controlled-release composition is provided. This method is characterized by forming a mixture of the above-defined monoglyceride and triglyceride in such amounts thereof that an L2-phase is formed when said mixture is contacted with the polar liquid selected from water, glycerol, ethylene glycol and propylene glycol, the biologically active material being added before, during or after the formation of said L2-phase. Generally this means that said active material is added to the L2-phase when formed but it can also be added e.g. to the polar liquid before said L2-phase is formed.

Before disclosing some preferable embodiments of the method according to the invention the following should be noted. Since water is the preferable polar liquid some aspects or embodiments of the invention will be described in connection with water. However, this does not mean that the general ideas are not similarly applicable to the other polar liquids mentioned.

The water aggregates of the L2-phase or the interfacial zone between the hydrophilic and hydrophobic regions of the phase provide the sites of controlled release as in the case of active substances solved in the phase. In the case of a very low solubility of the active substance in the phase it can be dispersed within the L2-phase. The L2-phase has a very low interfacial tension towards an outside water phase, and it is therefore easily emulsified into water. When a sensitive substance, e.g. a protein, is solubilized into the L2-phase, it must first be solved in the water phase. Then the protein solution is mixed with the monoglyceride-triglyceride mixture, the optimum weight ratio of last-mentioned mixture being 7:3, said mixing operation being performed by dropwisely adding the monoglyceride-triglyceride liquid to the protein solution. Only under these conditions it is possible to keep the native protein structure. If the drops are added to the protein solution with intervals around one second, the L2-phase formed will swell to the limit of water swelling between each addition. Thus the protein will keep the water environment needed during the whole preparation process.

Thus, one embodiment of the claimed method, which is of special interest in connection with sensible substances, such as proteins, is characterized by forming a solution of the active material in the polar liquid, preferably water, as well as a mixture of the monoglyceride and the triglyceride and adding the monoglyceride-triglyceride mixture dropwisely to the solution of said active material in the polar liquid.

The preparation in this way of a 5% (w/w) cytochrome c solution in water, which is then transferred into an L2-phase formed by monolein-soybean oil (weight 7:3) gives a final protein concentration in the L2-phase of 0.6%. When this L2-phase is kept in contact with a water phase, with 1 cm³ of each phase and 1 cm² in contact area in between, it takes about two days until the protein concentration in the outside water has reached the equilibrium value.

The preparation of L2-phase containing bioactive substances of more simple types, like hydrocortisone or vitamins, can be prepared by mere mixing of the ingredients in the desired proportions. Then it is just to wait for equilibrium to be reached, as the L2-phase is thermodynamically stable.

With reference to the method according to the invention it should also be added that those preferable embodiments which have been described above in connection with the composition are similarly applicable to the method and need not be repeated here.

Finally, the present invention also relates to the use of the above-mentioned L2-phase, including all preferable embodiments thereof, to encapsulate a biologically active material in order to obtain a preparation giving a controlled release of said biologically active material. As has been mentioned above this use is especially interesting in connection with ins-

ible substances such as proteins.

EXAMPLES

Some embodiments of the invention will now be described more in detail by the following non-limiting examples.

Example 1

10 100 mg of lysozyme is dissolved in 1 g of water. This solution is mixed at 40°C with a mixture of 3 g of soybean oil and 7 g of sunflower oil monoglycerides last-mentioned mixture being dropwisely added to said lysozyme solution. The L2-phase formed thereby exhibits a slow release of the protein molecules into water in the environment. A droplet thereof under the eye-lid will provide an antimicrobial effect during several hours.

20

Example 2

25 1 g of hydrocortisone is dissolved in an L2-phase prepared from 65 g of monolein, 27 g of olive oil, 5 g of propylene-glycole and 3 g of water. This liquid can be used for a transdermal administration of hydrocortisone.

30

Example 3

35 Benzylpenicillin is used in the form of a saturated water solution to form an L2-phase which consists of 13% (w/w) of penicillin solution, 60% of monolein and 27% (w/w) of soybean oil. The ingredients are mixed at room temperature until a transparent single phase is obtained. The penicillin is protected against acidic degradation in the stomach.

Claims

40 1. A controlled-release composition for a biologically active material, characterized in that said biologically active material has been dissolved or dispersed in an L2-phase comprising

45 (a) at least one monoglyceride of an unsaturated fatty acid having 16-22 carbon atoms or a vegetable or animal oil containing such a monoglyceride,

50 (b) at least one triglyceride of at least one unsaturated fatty acid having 16-22 carbon atoms or a vegetable or animal oil containing such triglycerides and

55 (c) at least one polar liquid selected from water, glycerol, ethylene glycol and propylene glycol.

2. A composition according to claim 1, characterized in that said monoglyceride is a monoglyceride of an unsaturated fatty acid having 18 carbon atoms

or a vegetable or animal oil containing the same.

3. A composition according to claim 2, characterized in that said monoglycerid is selected from monoolein and monolinolein in a vegetable or animal oil containing the same.

4. A composition according to anyone of the preceding claims, characterized in that said triglyceride is a triglyceride of an unsaturated fatty acid having 18 carbon atoms or a vegetable or animal oil containing the same.

5. A composition according to claim 4, characterized in that said triglyceride is in soybean oil.

6. A composition according to any one of the preceding claims, characterized in that the weight ratio of monoglyceride to triglyceride is within the range of from 1:1 to 3:1, preferably from 2:1 to 2.5:1, especially 7:3.

7. A composition according to any one of the preceding claims, characterized in that the biologically active material is selected from pharmaceutical compounds, such as antibiotics, proteins, steroids, vitamins and nucleic acids; compounds for agricultural uses, such as pesticides, fertilizers and trace elements; and feromones.

8. A composition according to any one of the preceding claims, characterized in that the biologically active material is present in an amount of 0,1-10% by weight of a ready-to-use composition.

9. A composition according to any one of the preceding claims, characterized by a water content of 4-12, preferably 5-10, % by weight.

10. A composition according to any one of the preceding claims, characterized by containing sodium chloride as a release rate modifying agent.

11. A pharmaceutical composition according to any one of the preceding claims, characterized in that it contains a pharmaceutically acceptable carrier useful for oral, rectal or transdermal administration or for inhalation.

12. A method of preparing a controlled-release composition according to any one of claims 1-11, characterized by forming a mixture of said monoglyceride and triglyceride in such amounts thereof that an L2-phase is formed when said mixture is contacted with the polar liquid selected from water, glycerol, ethylene glycol and propylene glycol, and adding the biologically active material to dissolve or disperse the same in said L2-phase, said addition being made before, during or after the formation of said L2-phase.

13. A method according to claim 12, which is especially useful for sensible substances such as proteins, characterized by forming a mixture of said monoglyceride and triglyceride, dissolving the biologically active material in the polar liquid, preferably water, and dropwisely adding the monoglyceride-triglyceride mixture to the solution of biologically active material in said polar liquid.

14. Use of an L2-phase as defined in any one of

claims 1-11 to encapsulate a biologically active material, particularly a protein, so as to obtain a preparation giving a controlled release of said biologically active material.

5

Revendications

1. Composition à libération contrôlée pour une substance biologiquement active, caractérisée en ce que ladite substance biologiquement active est dissoute ou dispersée dans une phase L2 comprenant :

(a) au moins un monoglycéride d'un acide gras insaturé possédant 16 à 22 atomes de carbone ou une huile végétale ou animale contenant un tel monoglycéride,

(b) au moins un triglycéride d'au moins un acide gras insaturé possédant 16 à 22 atomes de carbone ou une huile végétale ou animale contenant de tels triglycérides, et

(c) au moins un liquide polaire sélectionné parmi l'eau, le glycerol, l'éthylèneglycol et le propylène-glycol.

2. Composition selon la revendication 1, caractérisée en ce que ledit monoglycéride est un monoglycéride d'un acide gras insaturé possédant 18 atomes de carbone ou une huile végétale ou animale le contenant.

3. Composition selon la revendication 2, caractérisée en ce que ledit monoglycéride est sélectionné parmi la monoïléine et la monolinoléine ou une huile végétale ou animale les contenant.

4. Composition selon l'une quelconque des revendications précédentes, caractérisée en ce que ledit triglycéride est un triglycéride d'un acide gras insaturé possédant 18 atomes de carbone ou une huile végétale ou animale le contenant.

5. Composition selon la revendication 4, caractérisée en ce que ledit triglycéride se trouve dans de l'huile de soja.

6. Composition selon l'une quelconque des revendications précédentes, caractérisée en ce que le rapport pondéral du monoglycéride au triglycéride est compris dans la plage de 1:1 à 3:1, de préférence de 2:1 à 2.5:1, et est notamment égal à 7:3.

7. Composition selon l'une quelconque des revendications précédentes, caractérisée en ce que la substance biologiquement active est sélectionnée parmi des composés pharmaceutiques tels que des antibiotiques, des protéines, des stéroïdes, des vitamines et des acides nucléiques ; des composés à usage agricole, tels que des pesticides, des engrains et des oligo-éléments ; et des phéromones.

8. Composition selon l'une quelconque des revendications précédentes, caractérisée en ce que la substance biologiquement active est présente en une quantité comprise entre 0,1 et 10 % en poids d'une composition prête à l'emploi.

9. Composition selon l'une quelconque des revendications précédentes, caractérisée par un teneur en au comprise entre 4 et 12, de préférence entre 5 et 10 % en poids.

10. Composition selon l'une quelconque des revendications précédentes, caractérisée en ce qu'elle contient du chlorure de sodium comme agent modifiant la vitesse de libération.

11. Composition pharmaceutique selon l'une quelconque des revendications précédentes, caractérisée en ce qu'elle contient un véhicule pharmaceutiquement acceptable, utile pour l'administration orale, rectale ou percutanée ou pour l'inhalation.

12. Procédé de préparation d'une composition à libération contrôlée selon l'une quelconque des revendications 1 à 11, caractérisé par la formation d'un mélange desdits monoglycéride et triglycéride en des quantités telles que se forme une phase L2 lorsque ledit mélange est mis en contact avec le liquide polaire sélectionné parmi l'eau, le glycérol, l'éthyléneglycol et le propyléneglycol, et par l'addition de la substance biologiquement active en vue de sa dissolution ou sa dispersion dans ladite phase L2, ladite addition étant effectuée avant, pendant ou après la formation de ladite phase L2.

13. Procédé selon la revendication 12, particulièrement utile pour les substances sensibles telles que les protéines, caractérisé par la formation d'un mélange desdits monoglycéride et triglycéride, la dissolution de la substance biologiquement active dans le liquide polaire, de préférence de l'eau, et l'addition goutte à goutte du mélange de monoglycéride-triglycéride à la solution de substance biologiquement active dans ledit liquide polaire.

14. Emploi d'une phase L2 telle que définie dans l'une des revendications 1 à 11 pour encapsuler une substance biologiquement active, de préférence une protéine, de façon à obtenir une préparation permettant une libération contrôlée de ladite substance biologiquement active.

Patentansprüche

1. Zusammensetzung mit regulierter Freisetzung für ein biologisch aktives Material, dadurch gekennzeichnet, daß das biologisch aktive Material in einer L2-Phase gelöst oder dispergiert wurde, die folgende Komponenten umfaßt:

(a) wenigstens ein Monoglycerid einer ungesättigten Fettsäure mit 16 bis 22 Kohlenstoffatomen oder ein pflanzliches oder tierisches Öl, das ein solches Monoglycerid enthält;

(b) wenigstens ein Triglycerid wenigstens einer ungesättigten Fettsäure mit 16 bis 22 Kohlenstoffatomen der in pflanzliches oder tierisches Öl, das solche Triglycerid enthält; und

(c) wenigstens ein polares Flüssigkeit, gewählt

unter Wasser/Glycerin/Ethylenglykol und Propylenglykol.

2. Zusammensetzung nach Anspruch 1, dadurch gekennzeichnet, daß das Monoglycerid in Mino-glycerid einer ungesättigten Fettsäure mit 18 Kohlenstoffatomen oder ein pflanzliches oder tierisches Öl ist, das dieses Monoglycerid enthält.

3. Zusammensetzung nach Anspruch 2, dadurch gekennzeichnet, daß das Monoglycerid gewählt ist unter Monoolein und Monolinolein oder einem pflanzlichen oder tierischen Öl, das diese enthält.

4. Zusammensetzung nach irgendeinem der vorangehenden Ansprüche, dadurch gekennzeichnet, daß das Triglycerid ein Triglycerid einer ungesättigten Fettsäure mit 18 Kohlenstoffatomen oder ein pflanzliches oder tierisches Öl ist, das dieses Triglycerid enthält.

5. Zusammensetzung nach Anspruch 4, dadurch gekennzeichnet, daß das Triglycerid in Sojabohnenöl vorhanden ist.

6. Zusammensetzung nach irgendeinem der vorangehenden Ansprüche, dadurch gekennzeichnet, daß das Gewichtsverhältnis von Monoglycerid zu Triglycerid im Bereich von 1:1 bis 3:1 liegt, vorzugsweise von 2:1 bis 2,5:1, insbesondere bei 7:3.

7. Zusammensetzung nach irgendeinem der vorangehenden Ansprüche, dadurch gekennzeichnet, daß das biologisch aktive Material gewählt ist unter pharmazeutischen Verbindungen wie beispielsweise Antibiotika, Proteinen, Steroiden, Vitaminen und Nukleinsäuren, Verbindungen für landwirtschaftliche Zwecke wie beispielsweise Pestiziden, Düngemitteln und Spurenelementen und Pheromonen.

8. Zusammensetzung nach irgendeinem der vorangehenden Ansprüche, dadurch gekennzeichnet, daß das biologisch aktive Material in einer Menge von 0,1 bis 10 Gew.-% einer gebrauchsfertigen Zusammensetzung zugegen ist.

9. Zusammensetzung nach irgendeinem der vorangehenden Ansprüche, charakterisiert durch einen Wassergehalt von 4 bis 12 Gew.-%, vorzugsweise 5 bis 10 Gew.-%.

10. Zusammensetzung nach irgendeinem der vorangehenden Ansprüche, charakterisiert durch einen Gehalt an Natriumchlorid als Mittel zur Modifizierung der Freisetzungsgeschwindigkeit.

11. Pharmazeutische Zusammensetzung gemäß irgendeinem der vorangehenden Ansprüche, dadurch gekennzeichnet, daß sie einen pharmazeutisch annehmbaren Träger enthält, der nützlich ist für eine orale, rektale oder transdermale Verabreichung oder zur Inhalation.

12. Verfahren zur Herstellung einer Zusammensetzung mit regulierter Freisetzung gemäß irgendeinem der Ansprüche 1 bis 11, dadurch gekennzeichnet, daß man in Mischung des Monoglycerids und Triglycerids in solchen Mengen herstellt, daß eine L2-Phase gebildet wird, wenn die

Mischung mit der polaren Flüssigkeit in Kontakt
gebracht wird, die gewählt ist unter Wasser, Glycerin,
Ethylenglyk I und Propylenglyk I, und Zug ben des
biologisch aktiven Materials unter Lösen oder Disper-
gieren desselben in der L2-Phase, wobei die Zugabe
vor, während oder nach der Bildung der L2-Phase
erfolgt.

5

13. Verfahren nach Anspruch 12, welches insbe-
sondere nützlich ist für empfindliche Substanzen wie
beispielsweise Proteine, gekennzeichnet durch
Herstellen einer Mischung des Monoglycerids und
Triglycerids, Lösen des biologisch aktiven Materials
in der polaren Flüssigkeit, vorzugsweise Wasser, und
tropfenweise Zugabe der Monoglycerid-Triglycerid-
Mischung zur Lösung des biologisch aktiven Mate-
rials in der polaren Flüssigkeit.

10

14. Verwendung einer L2-Phase, wie sie in ir-
gendeinem der Ansprüche 1 bis 11 definiert ist, zum
Einkapseln eines biologisch aktiven Materials, vor-
zugsweise eines Proteins, unter Erhalt einer Zuberei-
tung, die eine regulierte Freisetzung des biologisch
aktiven Materials ergibt.

15

20

25

30

35

40

45

50

55

